Sanofi's Lixisenatide Shows Challenges Of Being Late Entrant In Class
Safety and efficacy of what would be sixth GLP-1 agonist seem solid, but FDA advisory committee notes concerns about allergic reactions, dosing and relative effectiveness.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.
The latest drug development news and highlights from our FDA Performance Tracker